Impact of Prophylactic Antibiotic Selection on the Prevention and Bacterial Flora of Surgical Site Infections After Colorectal Surgery. 2023

Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
Department of Ambulatory Care, NYC Health+Hospitals/Kings County, Brooklyn, New York, USA.

Deep incisional and organ/space surgical site infections (SSIs) after colorectal surgery are associated with adverse outcomes. Multiple antibiotic regimens are recommended for peri-operative prophylaxis, with no particular regimen preferred over another. We compared the prophylaxis regimens used in patients with and without SSIs, and the impact of regimens on the flora involved in SSIs. Information was extracted from the National Healthcare Safety Network databank of patients undergoing colorectal surgery from 2015 to 2022 in a large public healthcare system in New York City. Patients with SSIs were identified, and controlling for nine variables, propensity score matching was used to create a matched control group without SSIs. Prophylactic regimens were compared between the matched groups with and without SSIs. Also, for the patients with SSIs, the impact of the prophylactic regimen on the subsequent pathogens involved the infection was examined. A total of 275 patients with SSIs were compared to a matched cohort without SSIs. The prophylactic regimens were extremely similar between the SSI and control groups. Among the patients who developed SSIs, more patients who received cefoxitin had emergence of select cephalosporin-resistant Enterobacterales and Bacteroides spp. when compared with those who received β-lactam-β-lactamase inhibitors. The distribution of surgical prophylaxis regimens was remarkably similar between patients developing serious SSIs and a closely matched cohort that did not develop an SSI. However, given the downstream effects of more resistant and anaerobic flora should an infection develop, use of cefoxitin should be re-evaluated as a prophylactic agent.

UI MeSH Term Description Entries
D002440 Cefoxitin A semisynthetic cephamycin antibiotic resistant to beta-lactamase. Cefoxitin Sodium,MK-306,Mefoxin,Mefoxitin,Méfoxin,MK 306,MK306,Sodium, Cefoxitin
D003107 Colorectal Surgery A surgical specialty concerned with the diagnosis and treatment of disorders and abnormalities of the COLON; RECTUM; and ANAL CANAL. Proctology,Colon Surgery Specialty,Colon and Rectal Surgery Specialty,Rectal Surgery Specialty,Specialty, Colon Surgery,Specialty, Rectal Surgery,Surgery Specialty, Colon,Surgery Specialty, Colon and Rectal,Surgery Specialty, Rectal,Surgery, Colorectal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013530 Surgical Wound Infection Infection occurring at the site of a surgical incision. Postoperative Wound Infection,Infection, Postoperative Wound,Infection, Surgical Wound,Surgical Site Infection,Wound Infection, Postoperative,Wound Infection, Surgical,Infection, Surgical Site,Infections, Postoperative Wound,Infections, Surgical Site,Infections, Surgical Wound,Postoperative Wound Infections,Surgical Site Infections,Surgical Wound Infections,Wound Infections, Postoperative,Wound Infections, Surgical
D019072 Antibiotic Prophylaxis Use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications. Antibiotic Premedication,Premedication, Antibiotic,Antibiotic Premedications,Premedications, Antibiotic,Prophylaxis, Antibiotic

Related Publications

Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
February 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
March 2021, Antibiotics (Basel, Switzerland),
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
January 2023, Antibiotics (Basel, Switzerland),
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
April 2015, The Surgical clinics of North America,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
January 1980, Minerva ginecologica,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
October 2013, Medecine et maladies infectieuses,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
January 2017, Anesthesia and analgesia,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
January 2017, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
February 2017, AANA journal,
Marie Abdallah, and Subin Sunny, and Edwin Jimenez, and Subhan Ata, and Jennifer Lee, and Briana Episcopia, and Mary Fornek, and Valery Roudnitsky, and John Quale
January 2017, Obstetrics and gynecology,
Copied contents to your clipboard!